US Myelodysplastic Syndrome (MDS) Therapeutics Market Report 2022 to 2030

US Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis

$ 3999

The US Myelodysplastic Syndrome (MDS) therapeutics market is projected to grow from $1.9 Bn in 2022 to $3.9 Bn by 2030, registering a CAGR of 9.3% during the forecast period of 2022-30. The market for pharmaceuticals for myelodysplastic syndrome (MDS) is growing as a result of a number of factors, including a rise in pediatric population, improved awareness, the launch of novel drugs, government initiatives to provide target-specific therapy, and favorable reimbursement policies. Major global players in this market are Abbott, Boehringer Ingelheim International GmbH, Johnson & Johnson Private Limited, MEI Pharma Inc., MTW Endoskopie Manufaktur, Aprea Therapeutics, Dr. Reddy's Laboratories Ltd, AbbVie Inc., Acceleron Pharma, Inc., Mylan N.V., Bristol-Myers Squibb Company, Eisai Co., Ltd., and LGM Pharma.

ID: IN10USRD001 CATEGORY: Rare Diseases GEOGRAPHY: US AUTHOR: Gaurav Bhongale

Buy Now

US Myelodysplastic Syndrome (MDS) Therapeutics Market Executive Summary

The US Myelodysplastic Syndrome (MDS) therapeutics market is projected to grow from $1,9 Bn in 2022 to $3.9 Bn by 2030, registering a CAGR of 9.3% during the forecast period of 2022-30.

Myelodysplastic Syndromes (MDS), commonly referred to as preleukemia, are essentially hematological diseases where the bone marrow is unable to create enough new blood cells. This could affect one, two, or all three of the blood cell lineages collectively. There are many types of myelodysplastic syndromes, including those with ring sideroblasts, multilineage dysplasia, and others. The market for pharmaceuticals for myelodysplastic syndrome (MDS) is growing as a result of a number of factors, including a rise in the pediatric population, improved awareness, the launch of novel drugs, government initiatives to provide target-specific therapy, and favorable reimbursement policies. Major global players in Myelodysplastic Syndrome (MDS) therapeutics market are Abbott, Boehringer Ingelheim International GmbH, Johnson & Johnson Private Limited, MEI Pharma Inc., MTW Endoskopie Manufaktur, Aprea Therapeutics, Dr. Reddy's Laboratories Ltd, AbbVie Inc., Acceleron Pharma, Inc., Mylan N.V., Bristol-Myers Squibb Company, Eisai Co., Ltd., and LGM Pharma are a few other companies that are involved in the pharmaceutical industry.

Market Dynamics

Market Drivers

The rising prevalence of illnesses and the adoption of a sedentary lifestyle across the globe is anticipated to boost market expansion. In addition, the annual drug launches and advancements in treatment are some additional driving forces that will pave the way for the market's development. It is also anticipated that the significant number of pipeline medications will accelerate the market's overall growth. However, it is anticipated that issues including limited revenue possibilities and a substantial number of product recalls will severely slow the market's growth rate. The high costs associated with developing novel MDS treatments are also anticipated to open up a variety of new opportunities that will impact the market for myelodysplastic syndromes (MDS).

Market Restraints

Numerous limitations, such as limited income opportunities and significant product recalls, are predicted to limit the market's growth rate. Also, the high cost of therapy is one of the restraints in the Myelodysplastic Syndrome (MDS) therapeutics market.

Key players

Jazz Pharmaceuticals
Celgene Corporation
Acceleron Pharma
Astex Pharmaceuticals
Takeda Pharmaceutical Company
Pfizer Inc.
AbbVie Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

US Myelodysplastic Syndrome (MDS) Therapeutics Market Segmentation

By Drugs

Lenalidomide
Decitabine
Azacitidine
Luspatercept
Phase 3 Drugs

By Route of Administration

Parenterals
Oral

By End User

Hospital Pharmacy
Retail Pharmacy
Online

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.